Patent details

Basic Information

Publication number:

EP2794627

PCT Application Number:

US2012071063

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP128603917

PCT Publication Number:

WO2013096679

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

French Title of Invention:

NUCLÉOSIDES SUBSTITUÉS, NUCLÉOTIDES SUBSTITUÉS ET ANALOGUES DE CEUX-CI

German Title of Invention:

SUBSTITUIERTE NUKLEOSIDE, NUKLEOTIDE UND ANALOGA DAVON

SPC Number:

Dates

Filing date:

20/12/2012

Grant date:

26/09/2018

EP Publication Date:

29/10/2014

PCT Publication Date:

27/06/2013

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

26/09/2018

EP B1 Publication Date:

26/09/2018

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

20/12/2022

Expiration date:

20/12/2032

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

22/05/2019

 

 

Name:

Janssen BioPharma, Inc.

Address:

260 E. Grand Ave., 2nd Floor, South San Francisco, CA 94080, United States (US)

History of Owners

From:

19/09/2018

To:

22/05/2019

Name:

Alios Biopharma, Inc.

Address:

260-E Grand Avenue, 2nd Floor, South San Francisco, CA 94080, United States (US)

Agent

Name:

ARONOVA S.A.

From:

13/12/2018

Address:

PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)

To:

Inventor

1

Name:

WANG, Guangyi

Address:

United States (US)

2

Name:

SMITH, David, Bernard

Address:

United States (US)

3

Name:

DEVAL, Jerome

Address:

United States (US)

4

Name:

PRHAVC, Marija

Address:

United States (US)

5

Name:

BEIGELMAN, Leonid

Address:

United States (US)

Priority

1

Priority Number:

201161579560 P

Priority Date:

22/12/2011

Priority Country:

United States (US)

2

Priority Number:

201261613836 P

Priority Date:

21/03/2012

Priority Country:

United States (US)

Classification

IPC classification:

A61K 31/4184; A61K 31/4192; A61K 31/506; A61K 31/522; A61K 31/675; A61K 31/7068; A61K 31/7072; A61K 31/708; A61P 31/14; C07D 471/04; C07D 473/34; C07H 19/00; C07H 19/06; C07H 19/14; C07H 19/16; C12N 9/99;

Publication

Bulletin

Bulletin Heading:

CO

Bulletin edition number:

2019/07

Publication date:

11/06/2019

Description:

Section M : Transfers of property (Art. 53 of the law), change of name and/or address

European Patent Bulletin

1

Issue number:

201839

Publication date:

26/09/2018

Description:

Grant (B1)

2

Issue number:

201844

Publication date:

31/10/2018

Description:

Application number/publication number of the divisional application (Art. 76) changed

Deed

Change of owner(s)

Change Kind/ Decision Type:

Change of owner(s) name/address

Deed Number:

RC20190000208A

Date Registered:

22/05/2019

Licence Effective Date:

Licence Expiration Date:

Scope of Licence:

Deed Filer:

ARONOVA S.A.

Journal Edition Number:

Text:

Changement de nom

Country Code:

Updated Licence Number:

Terminated Licence Number:

Added Owner(s)

Name:

Janssen BioPharma, Inc.

Address:

260 E. Grand Ave., 2nd Floor, South San Francisco, CA 94080, United States (US)

Removed Pledgee

Name:

Address:

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

10/12/2021

Last Annual Fee Paid Number:

10

Last Annual Fee Paid Amount:

131 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages
22/05/2019	Request For Change	4
02/01/2019	Outgoing Correspondence	1
13/12/2018	Power Of Attorney	1